BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24900625)

  • 21. Scaffold hopping approach on the route to selective tankyrase inhibitors.
    Liscio P; Carotti A; Asciutti S; Ferri M; Pires MM; Valloscuro S; Ziff J; Clark NR; Macchiarulo A; Aaronson SA; Pellicciari R; Camaioni E
    Eur J Med Chem; 2014 Nov; 87():611-23. PubMed ID: 25299683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
    Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
    J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solution NMR assignment of the ARC4 domain of human tankyrase 2.
    Zaleska M; Pollock K; Collins I; Guettler S; Pfuhl M
    Biomol NMR Assign; 2019 Apr; 13(1):255-260. PubMed ID: 30847846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres.
    Cook BD; Dynek JN; Chang W; Shostak G; Smith S
    Mol Cell Biol; 2002 Jan; 22(1):332-42. PubMed ID: 11739745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of new dual binding TNKS inhibitors of Wnt signaling inhibition by pharmacophore modeling, molecular docking and bioassay.
    Pu Y; Zhang S; Chang Z; Zhang Y; Wang D; Zhang L; Li Y; Zuo Z
    Mol Biosyst; 2017 Jan; 13(2):363-370. PubMed ID: 27995250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase.
    Xu W; Lau YH; Fischer G; Tan YS; Chattopadhyay A; de la Roche M; Hyvönen M; Verma C; Spring DR; Itzhaki LS
    J Am Chem Soc; 2017 Feb; 139(6):2245-2256. PubMed ID: 28084734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
    Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Cytomegalovirus Inhibits the PARsylation Activity of Tankyrase--A Potential Strategy for Suppression of the Wnt Pathway.
    Roy S; Liu F; Arav-Boger R
    Viruses; 2015 Dec; 8(1):. PubMed ID: 26729153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and functional analysis of parameters governing tankyrase-1 interaction with telomeric repeat-binding factor 1 and GDP-mannose 4,6-dehydratase.
    Eisemann T; Langelier MF; Pascal JM
    J Biol Chem; 2019 Oct; 294(40):14574-14590. PubMed ID: 31375564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tankyrase Inhibition Attenuates Cardiac Dilatation and Dysfunction in Ischemic Heart Failure.
    Wang H; Segersvärd H; Siren J; Perttunen S; Immonen K; Kosonen R; Chen YC; Tolva J; Laivuori M; Mäyränpää MI; Kovanen PT; Sinisalo J; Laine M; Tikkanen I; Lakkisto P
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function.
    Chang P; Coughlin M; Mitchison TJ
    Nat Cell Biol; 2005 Nov; 7(11):1133-9. PubMed ID: 16244666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
    Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
    J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
    Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
    Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zinc binding catalytic domain of human tankyrase 1.
    Lehtiö L; Collins R; van den Berg S; Johansson A; Dahlgren LG; Hammarström M; Helleday T; Holmberg-Schiavone L; Karlberg T; Weigelt J
    J Mol Biol; 2008 May; 379(1):136-45. PubMed ID: 18436240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification.
    Langelier MF; Eisemann T; Riccio AA; Pascal JM
    Curr Opin Struct Biol; 2018 Dec; 53():187-198. PubMed ID: 30481609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.
    Yu M; Yang Y; Sykes M; Wang S
    J Med Chem; 2022 Apr; 65(7):5244-5273. PubMed ID: 35306814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
    Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.